Inflammatory Bowel Disease Treatment Market Segmentation:
Disease Indication Segment Analysis
The Crohn’s disease segment is estimated to gain the largest market share in the inflammatory bowel disease treatment market over the analyzed timeframe. The growth of the segment is backed by the increasing worldwide instances of this condition compared to UC. According to an NLM report from October 2024, CD prevalence ranged between 4.1 and 22.7, 0.0 and 3.6, 13.2 and 26.0, 0.0 and 0.6 per 100,000 in Europe, Asia & the Middle East, Oceania, and South America, respectively. Furthermore, the launch of several awareness programs and government campaigns, promoting early diagnosis and intervention, is propelling engagement in this segment.
Distribution Channel Segment Analysis
The hospital segment is expected to garner a significant share in the inflammatory bowel disease treatment market by 2035. The progress in this segment is ascribed to the rising patient flow in the hospitals and increasing spending on the medical system around the globe. This can be testified by a 2022 NLM article, stating that the proportion of hospital pharmaceutical expenditure in the total pharma spending accounted for up to 50.0% in Europe. Additionally, IBEF reported that hospitals in India secured USD 1.5 billion worth of foreign direct investment (FDI) in 2023, exhibiting a 24.0% and 43.0% increment from 2021 and 2020. This indicates a continuous capital influx and enlarging exposure in this segment.
Our in-depth analysis of the global inflammatory bowel disease treatment market includes the following segments:
|
Drug Class |
|
|
Disease Indication |
|
|
Distribution Channel |
|
